IV 
116TH CONGRESS 
1ST SESSION 
H. RES. 584 
Expressing support for the designation of September 2019 as ‘‘National 
Prostate Cancer Awareness Month’’. 
IN THE HOUSE OF REPRESENTATIVES 
SEPTEMBER 24, 2019 
Mr. PAYNE (for himself, Mr. MULLIN, and Mr. MEEKS) submitted the fol-
lowing resolution; which was referred to the Committee on Energy and 
Commerce, and in addition to the Committee on Ways and Means, for 
a period to be subsequently determined by the Speaker, in each case for 
consideration of such provisions as fall within the jurisdiction of the com-
mittee concerned 
RESOLUTION 
Expressing support for the designation of September 2019 
as ‘‘National Prostate Cancer Awareness Month’’. 
Whereas an estimated 3,110,403 men in the United States 
live with prostate cancer; 
Whereas, according to the National Cancer Institute, the per-
centage of newly diagnosed prostate cancer cases in men 
under 65 has significantly increased and stands at 41.9 
percent; 
Whereas 1 in 9 men in the United States will be diagnosed 
with prostate cancer in their lifetimes; 
VerDate Sep 11 2014 
01:42 Sep 25, 2019
Jkt 089200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6300
E:\BILLS\HR584.IH
HR584
pamtmann on DSKBC07HB2PROD with BILLS
•HRES 584 IH 
Whereas prostate cancer is the most commonly diagnosed 
nonskin cancer and the second-leading cause of cancer- 
related deaths among men in the United States; 
Whereas the American Cancer Society estimates that in 
2019, 174,650 men will be diagnosed with, and more 
than 31,620 men will die of, prostate cancer; 
Whereas the odds of developing prostate cancer rise rapidly 
after age 50; 
Whereas African-American men suffer from a prostate cancer 
incidence rate that is significantly higher than that of 
White men and have more than double the prostate can-
cer mortality rate than that of White men; 
Whereas some veterans are at an increased risk of prostate 
cancer due to chemical or radiation exposure during mili-
tary service; 
Whereas a study conducted at the Portland VA Medical Cen-
ter and Oregon Health and Science University found that 
veterans exposed to Agent Orange were at an increased 
risk for both developing prostate cancer and developing 
more aggressive forms of the disease; 
Whereas having a father or brother with prostate cancer 
more than doubles the risk of a man developing prostate 
cancer, with a higher risk for men who have a brother 
with the disease and the highest risk for men with several 
affected relatives; 
Whereas screening by a digital rectal examination and a pros-
tate-specific antigen blood test can detect the disease at 
the earlier, more treatable stages, which could increase 
the chances of survival for more than 5 years to nearly 
100 percent; 
VerDate Sep 11 2014 
01:42 Sep 25, 2019
Jkt 089200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6300
E:\BILLS\HR584.IH
HR584
pamtmann on DSKBC07HB2PROD with BILLS
•HRES 584 IH 
Whereas prostate cancer is almost always diagnosed with a 
needle biopsy where the prostate is mapped and tissue 
cores removed from at least a dozen sites; 
Whereas even with state-of-the-art laboratory techniques and 
specimen tracking, the peer-reviewed literature reports 
that as many as 2.5 percent of prostate biopsy patients 
are affected by biopsy tissue switching or contamination 
leading to misdiagnosis; 
Whereas misdiagnosis can result in inappropriate over- or 
under-treatment of men; 
Whereas only 30 percent of men survive more than 5 years 
if diagnosed with prostate cancer after the cancer has 
metastasized; 
Whereas there are no noticeable symptoms of prostate cancer 
in the early stages, making appropriate screening critical; 
Whereas ongoing research promises further improvements in 
prostate cancer prevention, early detection, and treat-
ment; and 
Whereas educating people in the United States, including 
health care providers, about prostate cancer and early de-
tection strategies is crucial to saving the lives of men and 
preserving and protecting families: Now, therefore, be it 
Resolved, That the House of Representatives— 
(1) expresses support for the designation of 
‘‘National Prostate Cancer Awareness Month’’; 
(2) declares that steps should be taken— 
(A) to raise awareness about the impor-
tance of screening methods for, and treatment 
of, prostate cancer; 
VerDate Sep 11 2014 
01:42 Sep 25, 2019
Jkt 089200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\HR584.IH
HR584
pamtmann on DSKBC07HB2PROD with BILLS
•HRES 584 IH 
(B) to encourage research— 
(i) to improve screening and treat-
ment for prostate cancer; 
(ii) to discover the causes of prostate 
cancer; and 
(iii) to develop a cure for prostate 
cancer; 
(C) support Medicare payment policies 
that will improve diagnostic accuracy and elimi-
nate prostate cancer misdiagnosis due to biopsy 
contamination or specimen switching; and 
(D) to continue to consider ways for im-
proving access to, and eliminating racial dis-
parities in, the quality of health care services 
for detecting and treating prostate cancer; and 
(3) calls on the people of the United States, in-
terest groups, and affected persons— 
(A) to promote awareness of prostate can-
cer; 
(B) to take an active role in the fight to 
end the devastating effects of prostate cancer 
on individuals, families, and the economy; and 
VerDate Sep 11 2014 
01:42 Sep 25, 2019
Jkt 089200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\HR584.IH
HR584
pamtmann on DSKBC07HB2PROD with BILLS
•HRES 584 IH 
(C) to observe National Prostate Cancer 
Awareness Month with appropriate ceremonies 
and activities. 
Æ 
VerDate Sep 11 2014 
01:42 Sep 25, 2019
Jkt 089200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6301
E:\BILLS\HR584.IH
HR584
pamtmann on DSKBC07HB2PROD with BILLS